Trial Profile
An Open-Label, Multi-Center, Phase IB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus a Single Pre-Treatment Dose of Obinutuzumab) in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Crefmirlimab (Primary) ; Glofitamab (Primary) ; Obinutuzumab (Primary) ; Polatuzumab vedotin (Primary) ; Tocilizumab
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Roche
- 17 Jan 2024 Planned End Date changed from 30 Nov 2024 to 30 Sep 2026.
- 17 Jan 2024 Planned primary completion date changed from 30 Nov 2024 to 30 Sep 2026.
- 17 Jan 2024 Status changed from recruiting to active, no longer recruiting.